Centre contributes to ‘sea sponge’ drug advance

A breast cancer drug called eribulin, originally derived from sea sponges, has recently been approved for use in the NHS. This is the first breast cancer drug to be approved in a decade and very good news for women with advanced, aggressive forms of the disease. Researchers in Leeds, led by Professor Chris Twelves, were heavily involved in the development of the drug. They contributed to two major clinical trials of more than 1,800 women with breast cancer that had started to spread to other parts of the body and compared the survival of women treated with eribulin to those given standard treatment.

Professor Twelves said:

Our clinical trials results showed a substantial improvement in survival for women with metastatic triple negative breast cancer, and a more modest, but significant, benefit for those with HER2 negative breast cancers. I am delighted by the news that the drug will now be available through the NHS.”

Image credit: Sponges, Twilight Zone Expedition Team 2007, NOAA-OE [Public domain], via Wikimedia Commons.

« Go back

Page last updated: 09/11/2016